 |
Top 29 Kidney Disease treatment startups
Oct 12, 2024 | By Jason Kwon | 30 |
These startups develop new treatments and diagnostics technologies for Kidney Disease, like stem cells, drug-delivery implants, targeted drugs.
1
Country: UK | Funding: £125M
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
2
Country: UK | Funding: $180.4M
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
3
Country: USA | Funding: $100M
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases.
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases.
4
Country: USA | Funding: $624M
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
5
Country: USA | Funding: $555.1M
Monogram Health is a nephrologists to deliver transformative kidney care services.
Monogram Health is a nephrologists to deliver transformative kidney care services.
6
Country: USA | Funding: $480.9M
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
7
Country: USA | Funding: $442.5M
Akebia Therapeutics develops treatments for ischemia and vascular diseases. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Pursuing a new standard of care for patients with anemia associated with chronic kidney disease (CKD)
Akebia Therapeutics develops treatments for ischemia and vascular diseases. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Pursuing a new standard of care for patients with anemia associated with chronic kidney disease (CKD)
8
Country: USA | Funding: $386M
Strive Health is a provider of care delivery models aimed at improving chronic kidney disease care.
Strive Health is a provider of care delivery models aimed at improving chronic kidney disease care.
9
Country: USA | Funding: $381M
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.
10
Country: UK | Funding: $351.7M
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
11
Country: USA | Funding: $266M
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
12
Country: Sweden | Funding: $210.4M
Calliditas Therapeutics, a specialty pharmaceutical company that develops pharmaceutical products in fields of unmet medical need. Its products include Nefecon, a treatment for IgA nephropathy and Busulipo, an alternative for myeloablation prior to bone marrow transplantation.
Calliditas Therapeutics, a specialty pharmaceutical company that develops pharmaceutical products in fields of unmet medical need. Its products include Nefecon, a treatment for IgA nephropathy and Busulipo, an alternative for myeloablation prior to bone marrow transplantation.
13
Country: USA | Funding: $210M
Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.
Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.
14
Country: USA | Funding: $198.8M
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
15
Country: Israel | Funding: $185M
Healthy.io de Dip.io, a home-based urinalysis kit that turns a smartphone into a clinical-grade diagnostic device. It’s the first smartphone-based urine test to secure clearance as a Class 2 device.
Healthy.io de Dip.io, a home-based urinalysis kit that turns a smartphone into a clinical-grade diagnostic device. It’s the first smartphone-based urine test to secure clearance as a Class 2 device.
16
Country: USA | Funding: $125.4M
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases.
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases.
17
Country: UK | Funding: $106.7M
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
18
Country: Singapore | Funding: $77.2M
AWAK develops wearable dialysis machines that operate and function like a normal kidney, for continuous dialysis.
AWAK develops wearable dialysis machines that operate and function like a normal kidney, for continuous dialysis.
19
Country: USA | Funding: $77.2M
AWAK develops wearable dialysis machines that operate and function like a normal kidney, for continuous dialysis.
AWAK develops wearable dialysis machines that operate and function like a normal kidney, for continuous dialysis.
20
Country: USA | Funding: $51M
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
